Amplification of mixed lineage leukemia gene perturbs hematopoiesis and cooperates with partial tandem duplication to induce acute myeloid leukemia
Genetic alternation of the mixed lineage leukemia (MLL) gene can be found in up to 10% of acute myeloid leukemia (AML).
1,2 Similar to MLL fusions and MLL partial tandem duplication (PTD), MLL amplification (MLL(n)) is reported in approximately 1% AML and myelodysplastic syndrome (MDS) associates with adverse treatment outcomes. 3, 4 In spite of the success in modeling AML induced by MLL fusions, 1 there has been no in vivo disease model for MLL(n) leukemia. On the other hand, while previous studies have proposed a recessive gain-of-function by MLL-PTD in suppressing the expression of wild-type MLL in normal karyotype haematologica 2017; 102:e300 LETTERS TO THE EDITOR Figure 1 . MLL amplification perturbs myeloid development in mouse models. Total cell counts in (A) bone marrow (2 femurs), (B) thymus and (C) spleen of the control MLL(0), MLL (10) (11) (12) (13) (14) (15) , and Mll PTD/WT mice. (D) Total colony numbers generated from bone marrow cells of MLL(n) and Mll PTD/WT mice. Bone marrow colonies were classified into burst forming unit-erythroid (BFU-E), colony forming unit-granulocyte (CFU-G), CFU-macrophage (CFU-M), CFU-granulocyte/macrophage (CFU-GM), and CFU-granulocyte/erythroid/macrophage/megakaryocyte (CFU-GEMM Intriguingly, MLL-PTD can be found to co-exist with MLL(n) in AML patients, 8, 9 suggesting an alternative pathological relationship between these 2 MLL aberrations in myeloid leukemogenesis.
To gain insights into the role of MLL(n) and MLL-PTD in hematopoietic development, we generated an in vivo mouse model of MLL amplification where the full-length human MLL cDNA was expressed under the murine Scl-promoter/3'enhancer (Online Supplementary Figure  S1A ), which has been successfully used to drive oncogene expression in hematopoietic stem and progenitor haematologica 2017; 102:e301 LETTERS TO THE EDITOR Figure  S2A,B) . These findings are consistent with previously reported Scl-enhancer's property 10 and in line with the expression level of MLL in human MDS/AML patients carrying 5-10 or more than 10 copies of MLL with, approximately, a 1.5-and 9-fold increase, respectively.
11
To investigate the impacts of MLL amplification on normal hematopoiesis, MLL(n) mice at three months old were analyzed in parallel with Mll PTD/WT mice and nontransgenic control (MLL(0)). Although no significant difference in total cellularity was found in bone marrow and thymus, a significant increase in splenic cells was observed in Mll Figure S2C) , providing a potential explanation for the lower cellularity observed in the spleen of MLL(n) mice. Functionally, Mll PTD/WT bone marrows produced approximately 4 times more colonies than those by MLL(n) and the control ( Figure 1D,E) . While the ratio between each colony type remained constant in Mll PTD/WT , MLL(80-100) had a significant increase in the percentage of colony forming units-granulocyte/monocyte (CFU-GM) and a decrease in the percentage of colony forming unit-granulocyte (CFU-G; Figure 1F ), consistent with a mild shift to immature myeloid. MLL(n) splenocytes showed a slightly but significantly higher colony forming ability ( Figure 1G,H) , where they consistently exhibited an increase in immature colony forming units-granulocyte/erythrocyte/macrophage/megakaryocyte (CFU-GEMM) and burst forming units-erythroid (BFU-E; Figure  1I ). The degrees of expansion were even more notable in MLL(n) mice with a higher copy number of the MLL transgene ( Figure 1G-I) , suggesting an aberrant selection of proliferative myeloid clones. While there was no apparent difference in the proportions of B cells and T cells in these mice (Online Supplementary Figure S3A) , an expansion of the Gr-1+Mac-1+ cell population was found in the MLL(80-100) spleen ( Figure 1J,K) . Consistently, a transient enhanced replating ability was observed in MLL(n) and Mll PTD/WT splenocytes ( Figure 1L ). Compared to non-transgenic controls, MLL (10) (11) (12) (13) (14) (15) and MLL(80-100) splenocytes, the latter in particular, were able to form a substantial number of secondary colonies ( Figure 1L ). Mll PTD/WT splenocytes were able to generate compact myeloid colonies even in the third round of replating ( Figure 1L,M) . In contrast, there was no obvious difference in the replating ability of bone marrow cells (Online Supplementary Figure S3B) , consistent with the observed phenotypes in these mice ( Figure 1A-C) .
Apart from a significant decrease in the percentage of common lymphoid progenitors (CLPs) in the bone mar- Supplementary Figure S3C-E) . RTqPCR confirmed the over-expression of MLL in c-kit + HSPC bone marrow cells, albeit to a lesser extent than in whole bone marrow cells in MLL(n) mice (Online Supplementary Figure S3F,G) , suggesting that mild overexpression of MLL or MLL-PTD alone has a rather limited impact on HSPC compartments. Consistently, none of the animals developed leukemia during two years of observation (Online Supplementary Figure S3H) , indicating that additional events are required for overt leukemia as observed in humans.
On the other hand, the recurrent reports of AML possessing both MLL(n) and MLL-PTD 8, 9 raise the intriguing possibility that these 2 different MLL aberrations may collaborate in acute leukemogenesis. (Figure 2A-D) . Examination of peripheral blood revealed anemia and circulating myeloblasts ( Figure 2E ), which also infiltrated the spleen and liver and resulted in an alteration in their normal architecture (Online Supplementary Figure S5 and Online Supplementary  Table S1 ). Flow cytometric analysis further confirmed expansion of Gr-1 + Mac-1 + c-kitlow myeloblasts (Online Supplementary Figure S6A) , which was in contrast to a drastic reduction of B220 + cells (Online Supplementary Figure S6B ). These results indicate that MLL amplification and MLL-PTD cooperate to block normal myeloid differentiation and to induce their aberrant expansion leading to overt AML.
To gain further molecular insights underlying these cooperating MLL aberrations, we assessed the transcriptional and epigenetic status of Hoxa9, a key downstream target for MLL leukemongenesis. ; showing the possibility of functional cooperation in MLL aberrations ( Figure 2F-G) . In addition to Hoxa9, a considerably higher level of Meis1, 1 another target for MLL leukemongenesis, was also detected in MLL(80-100) and MLL (40) (41) (42) (43) (44) (45) (46) (47) (48) (49) (50) PTD/WT bone marrow cells, which provides an explanation for the transformation in the double mutants (Online Supplementary Figure S7A) . To further confirm this finding in the relevant human disease, we also examined the expression and epigenetic status of HOXA9 in primary human AML blasts carrying both MLL(n) and MLL-PTD (Online Supplementary Figure  S7B ). HOXA9 was significantly over-expressed in all 3 MLL(n)-PTD samples and MLL-AF6 leukemia as compared to normal karyotype AML ( Figure 2H 14 They found that DOT1L inhibition abrogated H3K79me2 and led to downregulation of MLL targets in MLL-PTD leukemia cell lines, 14 suggesting that DOT1L is a potential therapeutic target for MLL-PTD leukemia. Consistent with the mouse model, we also observed similar histone modification patterns in human MLL(n)-PTD blasts ( Figure 3C ). While MLL(n)-PTD samples exhibited an increased H3K79me2 mark, it was significantly lower than that seen in MLL fusion leukemia. Conversely, H3K4me3 was invariably present at a high level in all MLL(n)-PTD samples ( Figure 3C ), which is in line with the detection of elevated expression of wild-type MLL in primary AML patients ( Figure 3D ), suggesting that H3K4me3 mediated by the MLL/SET family may also play a critical role for activation of downstream targets in these leukemias. To further test this hypothesis, pharmacological inhibition of MLL catalytic activity by a small molecule inhibitor WDR-010315 significantly reduced cell viability ( Figure  3E ), induced cell differentiation ( Figure 3F ) and repressed ribonucleic acid (RNA) expression of Meis1 ( Figure 3G 
